newsfilter
← Latest News
GlobeNewswire·

Artiva Biotherapeutics Reports Full Year 2024 Financial Results and Recent Business Highlights

Initial data for AlloNK® from autoimmune program expected H1 2025 Updated clinical data from Phase 1/2 trial exploring AlloNK + rituximab in NHL showing continued durability of response to be presented at a medical